- Home
- CNTB vs PIM Comparison
CNTB vs PIM Comparison
Compare CNTB & PIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNTB | PIM |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 153.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CNTB | PIM |
|---|---|---|
| Price | $1.97 | $3.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 302.6K | 70.1K |
| Earning Date | 08-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | ★ $64,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $63.40 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.23 | $3.07 |
| 52 Week High | $3.82 | $3.50 |
Technical Indicators
Market Signals| Indicator | CNTB | PIM |
|---|---|---|
| Relative Strength Index (RSI) | 37.41 | 45.46 |
| Support Level | $1.46 | $3.16 |
| Resistance Level | $2.05 | $3.33 |
| Average True Range (ATR) | 0.19 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.71 | 52.63 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About PIM Putnam Master Intermediate Income Trust
Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.